INSTITUTIONAL PRESENTATION

1

Disclaimer

The material that follows is a presentation of general background information about RaiaDrogasil S.A. (the "Company") as of the date of the presentation. It is information in summary form and does not purport to be complete. It is not intended to be relied upon as advice to potential investors. This presentation is strictly confidential and may not be disclosed to any other person. No representation or warranty, express or implied, is made concerning, and no reliance should be placed on, the accuracy, fairness, or completeness of the information presented herein.

This presentation contains statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933 (the "Securities Act") and Section 21E of the Exchange Act of 1934. Such forward-looking statements are only predictions and are not guarantees of future performance. Investors are cautioned that any such forward-looking statements are and will be, as the case may be, subject to many risks, uncertainties and factors relating to the operations and business environments of the Company that may cause the actual results of the companies to be materially different from any future results expressed or implied in such forward-looking statements.

Although the Company believes that the expectations and assumptions reflected in the forward-looking statements are reasonable based on information currently available to the Company's management, the Company cannot guarantee future results or events. The Company expressly disclaims a duty to update any of the forward looking-statements.

Our securities have not been and will not be registered under the Securities Act or under any state securities laws in the United States, and are being offered under exemptions from registration under the Securities Act. Securities may not be offered or sold in the United States unless they are registered or exempt from registration under the Securities Act. Any offering to be made in the United States will be made by means of an offering circular that may be obtained from the agents.

This presentation does not constitute an offer, or invitation, or solicitation of an offer, to subscribe for or purchase any securities. Neither this presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever.

2

Leading the consolidation of the pharmacy industry in Brazil.

200+ years

#1 pharmacy chain

of combined history of Raia

and 8th largest retailer in Brazil

Taking close care of

and Drogasil, merged in 2011

people's health and well-beingduring all times of their lives

2.4 thousand

Pharmacies

25 billion

Gross revenue (3Q21 LTM, R$) +21% Y/Y growth

271 million

Tickets (3Q21 LTM)

>48,000

Employees

260

New pharmacies in 2022 (guidance)

14.3%

Market share in the 3Q21

41 million

Active customers

AAA(bra) rating by Fitch

3

Secular demand growth and consolidation opportunity (1/2).

Fast population aging process

Number of years for the 65+ population to grow from 7% to 14%

Brazil (2011 - 2032) 21

China (2000 - 2026)

26

Japan (1970 - 1996)

26

Spain (1947 - 1992)

45

UK (1930 - 1975)

45

Canada (1944

- 2009)

65

USA (1944

- 2013)

69

Australia (1938 -2011)

73

Sweden (1890

- 1975)

85

France (1865

- 1980)

115

Source: Growing Old in an Older Brazil, The World Bank, 2011

Brazilian population above 65 years old

Millions

50,0

45,0

+15.6 MM seniors

CAGR = 2.8%

40,0

35,0

+13.8 MM seniors

30,0

CAGR = 4.2%

25,0

20,0

+6.4 MM seniors

CAGR = 3.4%

15,0

10,0

5,0

-

2000

2003

2006

2009

2012

2015

2018

2021

2024

2027

2030

2033

2036

2039

2042

2045

Source: Population Estimate 2000-2060, IBGE (Brazilian Institute of Statistical Geography), 2013

4

Secular demand growth and consolidation opportunity (2/2).

Brazilian pharmaceutical retail market

Pharmaceutical retail market share

R$ billions

126

113

103

96

85

75

66

58

50

43

36

30

11 12 13 15 17 19 21 21 25

'00 '01 '02 '03 '04 '05 '06 '07 '08 '09 '10 '11 '12 '13 '14 '15 '16 '17 '18 '19 '20

Source: IQVIA

9.2%

9.8%

10.8%

11.4%

11.8%

13.4%

13.5%

18.6%

17.5%

16.3%

16.4%

16.3%

16.0% 15.2%

22.5%

24.7%

24.9%

23.9%

23.3%

22.3%

21.8%

17.2%

15.9%

16.7%

17.6%

18.4%

19.1%

20.2%

32.5%

32.1%

31.3%

30.7%

30.3%

29.1%

29.2%

2014

2015

2016

2017

2018

2019

2020

Independents

Assoc./Franch.

Other Chains

Abrafarma #2 to 5

5

RD

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Raia Drogasil SA published this content on 11 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 January 2022 14:37:02 UTC.